The GRADE process begins with asking a clinically relevant, well-designed clinical question composed of four elements: a patient, problem, or population; an intervention; a comparison intervention; and an outcome. The second step in the GRADE system is to gather the best evidence to answer the question. The third step is assessing the quality of evidence and the confidence in the estimates of the treatment.
ADVANTAGES AND LIMITATIONS

GRADE
• Adopted by more than 65 organizations worldwide as an international standard for guideline development.
• Explicitly evaluates relevant outcomes and considers risks, benefits, patient expectations, and resource utilization in reaching recommendations.
• Using GRADE is difficult and requires expertise in statistics.
SORT
• Adopted by the American Academy of Dermatology.
• Simple and easily applied by authors and physicians.
• Advocates the use of patient-oriented rather than disease-oriented outcomes.
• Overly simplified instrument that is not applied internationally.
AGREE
• Validated instrument that assesses the quality of guideline development.
• Assesses six domains in guideline development: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence.
The fourth step of the process is assessing the values and preferences of the target population regarding their beliefs and expectations for their health and life. This step refers to the process in which individuals weigh the potential benefits, harms, costs, limitations, and inconveniences of treatment options in relation to one another. With this information, the panel is more equipped to accurately define the trade-off between the benefits (desirable outcome) and risks (undesirable consequences) for a particular intervention. Ideally, "the panel" (guideline developers) will conduct a systematic review summarizing relevant studies regarding the patient's values and preferences. The greater the variability or uncertainty in values and preferences, the more likely a weak recommendation is warranted (Andrews et al., 2013) .
The overall strength of recommendation is based on the balance of risks and benefits, the quality of evidence, the values and preferences of the patients, and costs required for the treatment. Each component is given equal weight in relation to the other components. This strength of recommendation ranges on a continuum of categories from "strongly for" to "strongly against" the intervention (Table  1) . If the panel is highly confident of the balance between desirable and undesirable consequences, they make a strong recommendation for (desirable outweighs undesirable) or against (undesirable outweighs desirable) an intervention (Andrews et al., 2013) .
Guideline panels may also choose to make special recommendations when there is insufficient evidence, for example, an "only-in-research" recommendation. This recommendation is used when further research may reduce uncertainty The fourth step evaluates the trade-off between risks and benefits, reflecting the best assessment of patients' perspective of the evidence before making the final recommendation (Guyatt et al., 2013) (Figure 1) .
The study design determines the initial quality of evidence rating. RCTs start as high-quality evidence, whereas observational studies begin as low-quality evidence. This ranking can be upgraded or downgraded based on specific factors that can affect the quality of evidence. Factors that can lower the quality of evidence include study limitations, inconsistencies in the results, indirectness of evidence, imprecision in the estimates, and publication bias. The rating can be upgraded if the study shows the presence of a dose-response effect or a large magnitude of the estimated effect.
After assessing all the domains, the body of evidence per outcome is categorized as high (++++), moderate (+++), low (++), or very low (+) (Mustafa et al., 2013) . The quality of evidence rating is summarized in the Evidence Profile (EP) table, which includes an explicit judgment of each factor that determines the quality of evidence. Table 2 is an example of a transparent and concise way of showing the guideline panel judgments about the domains. It also contains the Summary of Findings Table (SoF). The SoF is a quantitative assessment of the confidence in the estimates of effects (i.e., relative risk), without a qualitative judgment of the evidence rating that is provided in the EP table. The EP and the SoF tables serve different purposes and are directed toward different audiences. EP are intended for review authors and anyone who questions a quality of assessment. SoF are designated for a broader audience, such as users of systematic review and guidelines (Guyatt et al., 2011) . about the intervention and further research is considered of good value for the anticipated costs. Alternatively, the panel may decide not to make recommendations for or against a particular strategy if they find the strength in the estimate is too low, the trade-off between risks and benefits is too close, or values, preferences, and resource implications are not known (Andrews et al., 2013) . The main limitation for using GRADE is that it is a complex methodology with a steep learning curve.
RESEARCH TECHNIQUES MADE SIMPLE
STRENGTH OF RECOMMENDATION TAXONOMY (SORT)
SORT was developed by the editors of U.S. Family Medicine and Primary Care journals and the Family Practice Inquiries Network as an initiative to construct a unified taxonomy that allows authors to rate individual studies or bodies of evidence (Ebell et al., 2004) . The SORT approach is the main methodology that the American Academy of Dermatology utilizes in its guideline development process. The SORT process addresses the quality, quantity, and consistency of evidence, and it emphasizes the use of patient-oriented outcomes that measure changes in morbidity or mortality (Ebell et al., 2004) . The expert panel reviews the bodies of evidence for each of the recommendations and assigns a strength of recommendation on a scale of A through The desirable consequences are substantial (including substantial reduction in hospitalization, small but important reduction in mortality, and improvement in quality oflife that exceeds the minimal important difference) and valued highly. The undesirable consequences, inconvenience, and burden are relatively minor and associated with minimal disutility. We can be confident that patients place a high value on avoiding hospitalizations and mortality as well as improving quality oflife and a low value on avoiding the inconvenience associated with rehabilitation. We can be confident that these values vary little among patients with chronic respiratory disease.
Source of typical values (panel or study of general population or patients) Source of estimates of variability and extent of variability Method for determining values satisfactory for this recommendation
Resource implications Are the resources worth the expected net benefit from following the recommendation?
There are resources required to provide pulmonary rehabilitation but these are balanced by decreased resource needs as a result of decreased hospitalizations and net cost is well worth it given the desirable outcomes.
What are the costs per resource unit? Feasibility: Is this intervention generally available? Opportunity cost:
Is this intervention and its effects worth withdrawing or not allocating resources from other interventions Differences across settings:
Is there lots of variability in resource requirements across settings? Overall strength of recommendation S trong T he guideline panel recommends that patients with recent exacerbations of their COPD undergo pulmonary rehabilitation (Note: this is a hypothetical recommendation developed for this article and not intended for clinical decision making). Evidence to recommendation synthesis
The moderate-to-high confidence in the moderate-to-large magnitude of effects on highly valued outcomes, and the moderate-to-high confidence that undesirable outcomes are modest and their avoidance not highly valued suggest a strong recommendation.
COPD, chronic obstructive pulmonary disease.
Reprinted with permission from Andrews et al., 2013 . Figure. 1. The GRADE process. Adapted with permission from Guyatt et al., 2013. Table 2. Evidence to recommendation framework C. For example, consistent and good-quality evidence for treatment at an A-level rating would include a systematic review/meta-analysis with consistent results or a high-quality, large individual RCT.
RESEARCH TECHNIQUES MADE SIMPLE
An A-level recommendation is based on consistent and good-quality, patient-oriented evidence. A B-level recommendation is based on inconsistent or limited-quality patient-oriented evidence. A C-level recommendation is based on consensus, usual practice, opinion, diseaseoriented evidence, or case series for studies of diagnosis, treatment, prevention, or screening (Table 1 ). The main limitation of SORT is that it is an overly simplified instrument that is not applied internationally.
APPRAISAL OF GUIDELINES RESEARCH AND EVALUATION (AGREE)
Whereas GRADE and SORT evaluate the body of evidence to establish sound guidelines, the AGREE instrument assesses the quality of the development of clinical practice guidelines. The quality of guidelines is based on the confidence that potential biases have been addressed adequately, that recommendations are both internally and externally valid, and that they are feasible for practice. New or existing guidelines and updates of existing guidelines may be appraised with AGREE. It is a validated tool with a 4-point numerical scoring system, ranging from 1 (representing strongly disagree) to 4 (strongly agree). Scores reflecting inadequate quality are assigned a score ≤2. This instrument can be applied to any disease area, including those in diagnosis, health promotion, and treatment.
AGREE is composed of 23 key items encompassed within six domains. Each domain is intended to capture a different dimension of the guideline quality: scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence. The domain score is calculated by adding all of the individual item scores in a domain and standardizing the total as a percentage of the maximum possible score for that domain. Each domain score may be useful for comparing guidelines and will aid in the decision whether to use that guideline. There is no set threshold for the domain score by which to define a "good" or "bad" guideline. Finally, an overall assessment is made as to the quality of the guideline, taking each of the appraisal criteria into account and rating it as "strongly recommend," "recommend (with provisos or alteration)," "would not recommend," or "unsure" (AGREE Collaboration, 2001) .
Recently, AGREE was modified to AGREE II. The purpose of this updated version was to improve reliability, validity, and supporting documentation. The newer version continues to have 23 items and six domains, whereas the rating scale for each domain has become more detailed, using a 7-point rather than 4-point scale. Score 1 is assigned when there is no relevant information; scores between 2 and 6 are given when the domain does not meet the full criteria; and a maximum score of 7 is given to exceptional reports (AGREE Next Steps Consortium, 2009).
Factors that may decrease the strength of evidence
for randomized controlled trials (RCTs) in GRADE include all of the following except
